Anteris Technologies Global’s (AVR) Overweight Rating Reiterated at Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a report issued on Wednesday, Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 132.56% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Barclays raised shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $14.00.

Anteris Technologies Global Stock Down 3.0%

AVR stock opened at $6.45 on Wednesday. The company has a market capitalization of $628.62 million, a P/E ratio of -3.31 and a beta of 1.87. The company has a 50-day simple moving average of $8.32 and a 200 day simple moving average of $8.05. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. During the same period in the previous year, the company earned ($0.58) EPS. Equities analysts anticipate that Anteris Technologies Global will post -1.21 EPS for the current year.

Insiders Place Their Bets

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd purchased 272,695 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was bought at an average cost of $7.18 per share, with a total value of $1,957,950.10. Following the acquisition, the insider owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. The trade was a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have bought 1,554,730 shares of company stock valued at $11,694,513 and have sold 3,008,459 shares valued at $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Anteris Technologies Global during the 2nd quarter worth about $56,846,000. Nantahala Capital Management LLC acquired a new stake in Anteris Technologies Global during the 2nd quarter worth about $33,325,850. ADAR1 Capital Management LLC acquired a new stake in Anteris Technologies Global during the 2nd quarter worth about $30,979,000. Perceptive Advisors LLC raised its holdings in Anteris Technologies Global by 104.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after buying an additional 1,750,000 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in Anteris Technologies Global during the 2nd quarter worth about $6,350,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.